雅虎香港 搜尋

登入

搜尋結果

  1. www.jnj.comJohnson & Johnson: Changing health for humanity

    22 小時前 · With a focus on treating with pinpoint precision in the hardest-to-reach parts of the body, restoring anatomy and reimagining healing, our portfolio of smarter, less invasive, more personalized treatments is addressing the most complex diseases. Focus areas include: Interventional Solutions, Orthopaedics, Surgery and Vision.

    • Latest News

      A collection of stories that highlight the way Johnson ...

    • Innovation

      Meet Xiao-Yu Song, Global Head of Research & ...

    • Caring & Giving

      Melissa Martinez is a clinical scientist within Johnson ...

    • Personal Stories

      Nina Raver-Shapira, Ph.D., loves a challenge: The ...

    • Our Heritage

      For Women’s History Month, we’re ...

    • Suppliers

      Working with our valued partners, we uphold the highest ...

    • Careers

      Johnson & Johnson is an Affirmative Action and ...

    • Media Center

      2024 First-Quarter reported sales growth of 2.3% to ...

  2. www.retina.janssen.comretina-das-website - Janssen

    2024年5月26日 · We focus on patients with retinal eye diseases, from rare eye diseases to those all too common. We are pioneering innovations, such as investigational gene therapies, that hold the potential to transform lives. Because when it comes to saving sight, we’re all in. Explore our research.

    • janssen pharmaceutical hk1
    • janssen pharmaceutical hk2
    • janssen pharmaceutical hk3
    • janssen pharmaceutical hk4
    • janssen pharmaceutical hk5

  3. 其他人也問了

  4. hk.finance.yahoo.com › news › global-opioid-analgesic-marketGlobal Opioid Analgesic Market Forecast, 2024 to 2030, ...

    2024年5月28日 · The future of the global opioid analgesic market looks promising with opportunities in the hospital, retail pharmacy, drug store, and online pharmacy markets. The study includes a forecast for...

  5. www.janssen.com › japan › press-releaseテクリスタマブ、再発又は難治性の多発性骨髄腫に係る製造販売承 ...

    2024年5月22日 · ヤンセンファーマ株式会社（本社：東京都千代田区、代表取締役社長：關口修平、以下「ヤンセン」）は22日、B細胞成熟抗原（BCMA）及びCD3を標的とする二重特異性抗体テクリスタマブについて、再発又は難治性の多発性骨髄腫の治療薬として、製造販売承認申請を行いました。 テクリスタマブは、現在開発中の希釈せずに使用可能な皮下注製剤です。 そして多発性骨髄腫において日本で初めてかつ唯一 * の体重に応じた投与が可能なBCMA及びCD3を標的とするT細胞リダイレクト二重特異性抗体 1 で、治療選択肢が限られた治癒困難な多発性骨髄腫の治療薬として申請いたしました。 * 2024年5月現在、日本国内において。

  6. hk.joblum.com › job › associate-product-manager-janssenJob: Associate Product Manager [Janssen] at Johnson & ...

    2024年5月29日 · Associate Product Manager [Janssen] Johnson & Johnson (Hong Kong) Ltd. Yau Tsim Mong District. Posted May 29, 2024. Apply Now. Job Description. About Johnson & Johnson. At Johnson & Johnson, we believe health is everything.

  7. www.careers.jnj.com › janssen-global-market-access-postGlobal Market Access Post-Doctoral Program | Johnson & ...

    4 天前 · The Global Market Access Post-Doctoral Program offers fellows in Global Market Access advanced training and mentorship to prepare them for success. The program is designed to harness the skills of candidates who are expected to receive or who have recently received a relevant doctoral degree in the last 12 months.

  8. global.chinadaily.com.cn › a › 202112Janssen Pharmaceutical Companies sign MoU with Amoy Diagnostics

    3 天前 · The Janssen Pharmaceutical Companies of Johnson & Johnson signs an MoU on strategic collaboration with Amoy Diagnostics Co Ltd on Sunday to reinforce partnership with local diagnostic companies to build up a collaborative biopharmaceutical ecosystem to optimize drug life cycle and empower full-cycle patient management.